Cargando…

MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to drive pro-tumorigenic gene expression programs, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Popay, Tessa M, Wang, Jing, Adams, Clare M, Howard, Gregory Caleb, Codreanu, Simona G, Sherrod, Stacy D, McLean, John A, Thomas, Lance R, Lorey, Shelly L, Machida, Yuichi J, Weissmiller, April M, Eischen, Christine M, Liu, Qi, Tansey, William P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793627/
https://www.ncbi.nlm.nih.gov/pubmed/33416496
http://dx.doi.org/10.7554/eLife.60191
Descripción
Sumario:The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to drive pro-tumorigenic gene expression programs, providing their role in MYC activity is understood. Here we interrogate how one MYC co-factor, host cell factor (HCF)–1, contributes to MYC activity in a human Burkitt lymphoma setting. We identify genes connected to mitochondrial function and ribosome biogenesis as direct MYC/HCF-1 targets and demonstrate how modulation of the MYC–HCF-1 interaction influences cell growth, metabolite profiles, global gene expression patterns, and tumor growth in vivo. This work defines HCF-1 as a critical MYC co-factor, places the MYC–HCF-1 interaction in biological context, and highlights HCF-1 as a focal point for development of novel anti-MYC therapies.